Utilizing angiogenic agents to expedite the neovascularization process in skin flaps.
The revascularization of a skin flap after flap transposition is an important step in flap survival. This study investigates the efficacy of certain angiogenic agents to expedite the neovascularization process and to increase the viability of skin flaps. Eighty-four island skin flaps were designed on the auricles of 42 New Zealand White rabbits to achieve 90% necrosis over a 7-day period. Thirty-six flaps were treated with Endothelial Cell Growth Supplement (ECGS) or Endothelial Cell Growth Factor (ECGF) at several concentrations topically or immersed in Gelfoam. The remaining flaps were used as normal saline controls. Flap viability and peripheral neovascularization were documented by polar planimetry, angiography, and histological analysis. The flap viability of the ECGS-Gelfoam -treated flaps was 100% greater than their normal saline-Gelfoam controls (p = .021). Flap angiograms demonstrated increased vascular ingrowth among the treated flaps compared to the controls. This study suggests that angiogenic agents can expedite flap neovascularization and have the potential to increase flap viability.
D000287:Administration, Topical; D000818:Animals; D003692:Delayed-Action Preparations; D016228:Endothelial Growth Factors; D005781:Gelatin Sponge, Absorbable; D006085:Graft Survival / Q000187:drug effects; D006133:Growth Substances / Q000008:administration & dosage*; D006801:Humans; D009336:Necrosis; D009389:Neovascularization, Pathologic / Q000000981:diagnostic imaging / Q000473:pathology; D011817:Rabbits; D011859:Radiography; D012867:Skin / Q000098:blood supply* / Q000473:pathology; D013524:Surgical Flaps
D003692:Delayed-Action Preparations; D016228:Endothelial Growth Factors; D006133:Growth Substances